TABLE 5.
Basic Kras-based GEMMs
| GEMM | Lesions (Incidence %) | Observations | References | ||
|---|---|---|---|---|---|
| PanIN | PDAC | MET | |||
| Elastase-TGF-α | 100 | 10 | No | KrasG12D accelerates progression of PanIN | 278 |
| Elastase-KRASG12D | 100 (CPN) | No | No | Acinar expression of human KRASG12D drives CPN with ductal histotype | 279 |
| Pdx1-Cre; K-Ras+/LSLG12D (KC model) | 100 | <20 | Yes | Impossibility to assess cell of origin Inflammation accelerates EMT and PanIN |
102,104,280 |
| Ptf1a-Cre; K-Ras+/LSLG12D | 100 | <20 | Yes | Impossibility to assess cell of origin | 102 |
| Elastase-tTA; Tet-O-Cre; K-Ras+/LSLG12Vgeo | 90 | 10 | No | Pancreatitis accelerates PanIN development | 125 |
| Nestin-Cre; K-Ras+/LSLG12D | 100 | No | No | Short survival due to CNS complications. PDAC initiation & progression accelerated by AP |
281,282 |
| Elastase-tTA; Tet-O-Cre; K-Ras+/LSLG12Vgeo plus cerulein | 100 | 20 | No | PanIN development requires pancreatitis | 125 |
| Elastase-CreER; K-Ras+/LSLG12D | 36 | NA | No | Leaky sperm. Short-term study. | 283 |
| Elastase-CreERT2; K-Ras+/LSLG12D | 63 | No | No | PanIN development does not require pancreatitis | 284 |
| Mist1-CreERT2; K-Ras+/LSLG12D | 30 | No | No | PanIN development does not require pancreatitis | 284 |
| Pdx1-CreER; K-Ras+/LSLG12D | 55 | Rare | No | The system may target acinar and precursor cells | 285 |
| proCPA1CreERT2; K-RasLSLG12D | 10 | No | No | PanIN development requires pancreatitis in older mice (5–8 weeks; PanIN in 33% mice) | 285 |
| RipCreER; K-Ras+/LSLG12D | 0 | No | No | Cooperation with pancreatitis | 285 |
NA indicates not analyzed; CPN, cystic papillary neoplasms.